Cargando…
Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil
The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac. This was a cross-sectional study involving 358 indi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539673/ https://www.ncbi.nlm.nih.gov/pubmed/34696277 http://dx.doi.org/10.3390/vaccines9101169 |
_version_ | 1784588804050386944 |
---|---|
author | Bichara, Carlos David Araújo Queiroz, Maria Alice Freitas da Silva Graça Amoras, Ednelza Vaz, Gergiane Lopes Vallinoto, Izaura Maria Vieira Cayres Bichara, Cléa Nazaré Carneiro do Amaral, Isabella Pinheiro Costa Ishak, Ricardo Vallinoto, Antonio Carlos Rosário |
author_facet | Bichara, Carlos David Araújo Queiroz, Maria Alice Freitas da Silva Graça Amoras, Ednelza Vaz, Gergiane Lopes Vallinoto, Izaura Maria Vieira Cayres Bichara, Cléa Nazaré Carneiro do Amaral, Isabella Pinheiro Costa Ishak, Ricardo Vallinoto, Antonio Carlos Rosário |
author_sort | Bichara, Carlos David Araújo |
collection | PubMed |
description | The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac. This was a cross-sectional study involving 358 individuals divided into two groups. Group 1 consisted of 205 volunteers who were tested for anti-SARS-CoV-2 total antibodies; group 2 consisted of 153 individuals tested for the presence of anti-SARS-CoV-2 neutralizing antibodies. Seropositivity was greater than 70% in both groups, although 17.6% and 20.9% of individuals showed no neutralizing or total antibody reactivity, respectively. The frequency of anti-SARS-CoV-2 total antibodies displayed a significantly different distribution between the sexes but not according to age. The frequency of anti-SARS-CoV-2 neutralizing antibodies was 93.3% (95% CI 68.1–99.8) in the age group from 21 to 40 years but significantly decreased with advancing age, and was 76.2% (95% CI 52.8–91.8) for 41 to 60 years, 72.5% (95% CI 62.8–80.9) for 61 to 80 years, and 46.7% (95% CI 21.3–73.4) for >80 years. Our results reveal a high prevalence of anti-SARS-CoV-2 total antibodies and anti-SARS-CoV-2 neutralizing antibodies in individuals who received both doses of the Coronavac vaccine, suggesting a lower effectiveness of the humoral immune response among those older than 60 years of age, which might be associated with senescence of the immune system. |
format | Online Article Text |
id | pubmed-8539673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85396732021-10-24 Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil Bichara, Carlos David Araújo Queiroz, Maria Alice Freitas da Silva Graça Amoras, Ednelza Vaz, Gergiane Lopes Vallinoto, Izaura Maria Vieira Cayres Bichara, Cléa Nazaré Carneiro do Amaral, Isabella Pinheiro Costa Ishak, Ricardo Vallinoto, Antonio Carlos Rosário Vaccines (Basel) Communication The present study evaluated the frequency of seropositivity for anti-SARS-CoV-2 (S1 and S2) total antibodies and anti-SARS-CoV-2 (receptor binding domain-RBD-S1) neutralizing antibodies in individuals vaccinated with the immunizing agent Coronavac. This was a cross-sectional study involving 358 individuals divided into two groups. Group 1 consisted of 205 volunteers who were tested for anti-SARS-CoV-2 total antibodies; group 2 consisted of 153 individuals tested for the presence of anti-SARS-CoV-2 neutralizing antibodies. Seropositivity was greater than 70% in both groups, although 17.6% and 20.9% of individuals showed no neutralizing or total antibody reactivity, respectively. The frequency of anti-SARS-CoV-2 total antibodies displayed a significantly different distribution between the sexes but not according to age. The frequency of anti-SARS-CoV-2 neutralizing antibodies was 93.3% (95% CI 68.1–99.8) in the age group from 21 to 40 years but significantly decreased with advancing age, and was 76.2% (95% CI 52.8–91.8) for 41 to 60 years, 72.5% (95% CI 62.8–80.9) for 61 to 80 years, and 46.7% (95% CI 21.3–73.4) for >80 years. Our results reveal a high prevalence of anti-SARS-CoV-2 total antibodies and anti-SARS-CoV-2 neutralizing antibodies in individuals who received both doses of the Coronavac vaccine, suggesting a lower effectiveness of the humoral immune response among those older than 60 years of age, which might be associated with senescence of the immune system. MDPI 2021-10-12 /pmc/articles/PMC8539673/ /pubmed/34696277 http://dx.doi.org/10.3390/vaccines9101169 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Bichara, Carlos David Araújo Queiroz, Maria Alice Freitas da Silva Graça Amoras, Ednelza Vaz, Gergiane Lopes Vallinoto, Izaura Maria Vieira Cayres Bichara, Cléa Nazaré Carneiro do Amaral, Isabella Pinheiro Costa Ishak, Ricardo Vallinoto, Antonio Carlos Rosário Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title | Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title_full | Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title_fullStr | Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title_full_unstemmed | Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title_short | Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil |
title_sort | assessment of anti-sars-cov-2 antibodies post-coronavac vaccination in the amazon region of brazil |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539673/ https://www.ncbi.nlm.nih.gov/pubmed/34696277 http://dx.doi.org/10.3390/vaccines9101169 |
work_keys_str_mv | AT bicharacarlosdavidaraujo assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT queirozmariaalicefreitas assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT dasilvagracaamorasednelza assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT vazgergianelopes assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT vallinotoizauramariavieiracayres assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT bicharacleanazarecarneiro assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT doamaralisabellapinheirocosta assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT ishakricardo assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil AT vallinotoantoniocarlosrosario assessmentofantisarscov2antibodiespostcoronavacvaccinationintheamazonregionofbrazil |